Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 7/20 | 0.85 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.85 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.61 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | POLR1A | O95602 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8224795 | 1.00 | RAD52 (0.85) | RAD52SMARCA2UHRF1AOX1PTK2 | |
| Hydrochloric Acid SCHEMBL10866302 | 0.99 | RAD52 (0.87) | RAD52SMARCA2UHRF1AOX1PTK2 | |
| SCHEMBL7573561 | 0.89 | RAD52 (0.68) | RAD52SMARCA2UHRF1NQO2HPGD | |
| SCHEMBL10865015 | 0.87 | RAD52 (0.66) | RAD52SMARCA2UHRF1AOX1POLR1A | |
| SCHEMBL24684963 | 0.85 | RAD52 (0.76) | RAD52SMARCA2UHRF1AOX1POLR1A | |
| Hydrochloric Acid SCHEMBL10866187 | 0.84 | RAD52 (0.78) | RAD52SMARCA2UHRF1AOX1POLR1A | |
| SCHEMBL7568056 | 0.84 | RAD52 (0.61) | RAD52SMARCA2UHRF1NQO2HPGD | |
| SCHEMBL26459020 | 0.83 | RAD52 (0.98) | RAD52SMARCA2UHRF1AOX1POLR1A | |
| SCHEMBL26459018 | 0.82 | RAD52 (0.74) | RAD52SMARCA2UHRF1AOX1PTK2 | |
| SCHEMBL5886244 | 0.81 | RAD52 (0.67) | RAD52SMARCA2UHRF1AOX1POLR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3226909-B1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20220304993-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| EP-3986471-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220304993-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | NQO1, HNMT, PNMT | RAD52 1224/4885SMARCA2 4597/4885UHRF1 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.